These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 12442664)

  • 1. Dopamine receptors in Parkinson's disease: imaging studies.
    Stoessl AJ; de la Fuente-Fernández R
    Adv Neurol; 2003; 91():65-71. PubMed ID: 12442664
    [No Abstract]   [Full Text] [Related]  

  • 2. Single-photon emission tomography and dopamine transporter imaging in Parkinson's disease.
    Marek K; Jennings D; Seibyl J
    Adv Neurol; 2003; 91():183-91. PubMed ID: 12442677
    [No Abstract]   [Full Text] [Related]  

  • 3. Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? For.
    Tatsch K
    Eur J Nucl Med Mol Imaging; 2002 May; 29(5):711-4. PubMed ID: 11976813
    [No Abstract]   [Full Text] [Related]  

  • 4. [Functional neuroimaging in movement disorders].
    Borbély K
    Orv Hetil; 2001 Oct; 142(43):2347-55. PubMed ID: 11760452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo snapshots of the dopaminergic synapse in small animals.
    Nikolaus S; Beu M; Wirrwar A; Antke C; Müller HW
    Mol Psychiatry; 2005 Jun; 10(6):516-8. PubMed ID: 15920466
    [No Abstract]   [Full Text] [Related]  

  • 6. Function of sigma1 receptors in Parkinson's disease.
    Mishina M; Ishiwata K; Ishii K; Kitamura S; Kimura Y; Kawamura K; Oda K; Sasaki T; Sakayori O; Hamamoto M; Kobayashi S; Katayama Y
    Acta Neurol Scand; 2005 Aug; 112(2):103-7. PubMed ID: 16008536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? Against.
    Frey KA
    Eur J Nucl Med Mol Imaging; 2002 May; 29(5):715-7. PubMed ID: 11976814
    [No Abstract]   [Full Text] [Related]  

  • 8. Functional imaging of neurotransmitter systems in movement disorders.
    Ilgin N
    Q J Nucl Med; 1998 Sep; 42(3):179-92. PubMed ID: 9796366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine transporter imaging.
    Lees AJ; Grosset DG
    Mov Disord; 2003 Oct; 18 Suppl 7():S1-2. PubMed ID: 14531038
    [No Abstract]   [Full Text] [Related]  

  • 10. Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects.
    Kim HJ; Im JH; Yang SO; Moon DH; Ryu JS; Bong JK; Nam KP; Cheon JH; Lee MC; Lee HK
    J Nucl Med; 1997 Nov; 38(11):1703-11. PubMed ID: 9374337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain.
    Madras BK; Gracz LM; Fahey MA; Elmaleh D; Meltzer PC; Liang AY; Stopa EG; Babich J; Fischman AJ
    Synapse; 1998 Jun; 29(2):116-27. PubMed ID: 9593102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease.
    Morrish PK
    JAMA; 2002 Jul; 288(3):312; author reply 312-3. PubMed ID: 12117387
    [No Abstract]   [Full Text] [Related]  

  • 13. Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease.
    Albin RL; Nichols TE; Frey KA
    JAMA; 2002 Jul; 288(3):311-2; author reply 312-3. PubMed ID: 12117386
    [No Abstract]   [Full Text] [Related]  

  • 14. Dopamine transporter imaging with fluorine-18-FPCIT and PET.
    Kazumata K; Dhawan V; Chaly T; Antonini A; Margouleff C; Belakhlef A; Neumeyer J; Eidelberg D
    J Nucl Med; 1998 Sep; 39(9):1521-30. PubMed ID: 9744335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single photon emission computed tomography imaging of dopaminergic function: presynaptic transporter, postsynaptic receptor, and "intrasynaptic" transmitter.
    Innis RB
    Adv Pharmacol; 1998; 42():215-9. PubMed ID: 9327882
    [No Abstract]   [Full Text] [Related]  

  • 16. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for beta-CFT binding with positron emission tomography.
    Ouchi Y; Yoshikawa E; Okada H; Futatsubashi M; Sekine Y; Iyo M; Sakamoto M
    Ann Neurol; 1999 May; 45(5):601-10. PubMed ID: 10319882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT.
    Booij J; Hemelaar TG; Speelman JD; de Bruin K; Janssen AG; van Royen EA
    J Nucl Med; 1999 May; 40(5):753-61. PubMed ID: 10319746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Baldwin RM; Zoghbi S; Zea-Ponce Y; Charney DS; van Dyck CH; Hoffer PB; Innis RB
    J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease.
    Hwang WJ; Yao WJ; Wey SP; Ting G
    J Nucl Med; 2004 Feb; 45(2):207-13. PubMed ID: 14960637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease: in vivo assessment of disease progression using positron emission tomography.
    Au WL; Adams JR; Troiano AR; Stoessl AJ
    Brain Res Mol Brain Res; 2005 Mar; 134(1):24-33. PubMed ID: 15790527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.